Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 10Phase 3 7Phase 4 4Phase 2/3 2Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Gynecologic 1

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Everolimus 2lutetium Lu 177 dotatate 1Somatostatin 1Sirolimus 1Positron Emission Tomography Computed Tomography 1Oxaliplatin 1Leucovorin 1Injections 1Fluorouracil 1Bevacizumab 1Axitinib 1Al18F-NOTA-octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Everolimus × NET × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡